36 Medidata Solutions Testimonials

“Visibility into patient reporting helps us mitigate protocol compliance issues early in the study rather than later, when it’s harder.”

“Our partnership with Medidata has enabled us to offer top-notch service to sponsors. In the last decade, we’ve embraced the latest Rave EDC technology, including eCOA/ePRO via the Patient Cloud and Rave Coder. We’ve successfully configured intricate study designs, from early-phase oncology with numerous protocol changes to rare disease studies with diverse data collection methods.”

“The partnership with Medidata further underscores TissueTech’s commitment to evidence-based medicine, scientific integrity and continuous research and innovation. Medidata’s unified platform provides us with the technology foundation to scale our clinical research, address the complexity of today’s clinical trials, and build and maintain efficiencies as we continue to grow.”

“It is to everyone’s advantage to [use Medidata’s] unified platform so that there is one login. There is one way that people are accessing all the things they need to do with their data. If we’re thinking of patients and sites first, we have to think about that value…[so] they’re not worried about having multiple laptops and multiple logins.”

“We used to do all the reconciliation manually. With the Rave Site Payment, it’s automated the payments not only from a sponsor’s perspective but also from the site’s perspective. Sites don’t have to do anything additional. From a sponsor perspective, we have all the line item details. We can see what’s paid to the site [and] what’s outstanding. The same applies to the sites. They can go into the system, see what’s been paid and what’s outstanding, and then work collaboratively to fix or expedite things if needed.”

“What Medidata brings to the table, in addition to deep subject matter expertise, is the willingness to keep working until it is right. We can’t do that’ was never a phrase we heard from their Professional Services team.”

“The Professional Services group is an absolutely incredible resource. They taught me everything I needed to know so I could do it myself—quickly, easily and correctly… the first time.”

"Using MS Word documents for visit reporting wasted our CRAs’ time and the reviewer’s time. With Medidata’s cloud-based CTMS, which structures visit report data, CRAs spend 40 percent less time completing a report and site correspondences. We’ve also noticed a reduction in review-to-approval cycle times from 16 days to seven days."

“The team of Professional Services that I work with is very intelligent and collaborative We enjoy working with Medidata, it’s a great team. They’re always willing to come to the table and discuss our needs.”

“Everything is there in one place. We can filter by site, we can filter by what’s been dispensed, and it’s really easy for us to track.”

“We’re investing in technology to help us unlock cancer’s secrets, and Medidata’s cloud-based platform provides us with the flexibility and scalability we need to accelerate progress.”

“We chose to partner with Medidata because we recognize that we need an innovative technology partner with deep understanding of CROs and sites and sponsors in order for us to excel in this market. Medidata delivers the right platform, expertise and services that will allow us to be competitive and aggressively scale our full service offerings.”

"We want to use the best in-class technology and we want to combine that with our clinical research."

“One of the things that attracted me to Medidata was their ability to have a support mechanism [beyond] internal experts. Having a broad reach across the globe and supporting end users with devices are important. These factors attracted me to the Medidata DCT Program because not all competitors have that reach with their help desk and device support. It’s nice to have a reputable organization that allows us to lean on."

“Having our documentation in a secure, validated environment enables an ease of use for authoring, review, and approval. This allows us to pay attention to other things so we can focus on our product development.”